共 57 条
[1]
BjORnsson ES(2013)Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland [J] Gastroenterology 144 19-20
[2]
Bergmann OM(2014)ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J] Am J Gastroenterol 109 950-966
[3]
BjORnsson HK(2007)Clinical analysis of 275 cases of acute drug-induced liver disease [J] Front Med 1 58-61
[4]
Chalasani NP(2010)An analysis of 66 cases of drug-induced liver injury Zhonghua Gan Zang Bing Za Zhi 18 715-716
[5]
Hayashi PH(2013)DMARDs (disease-modifying antirheumatic drugs) [J]. Nihon Rinsho Japanese J Clin Med 71 1199-765
[6]
Bonkovsky HL(2017)Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan Mod Rheumatol 27 755-16
[7]
Li L(2007)Long-term safety study of iguratimod in patients with rheumatoid arthritis [J] Mod Rheumatol 17 10-144
[8]
Jiang W(2014)Clinical features, diagnosis, and natural history of drug-induced liver injury [J] Semin Liver Dis 34 134-121
[9]
Wang J(2017)Calvaruso V.A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort Eur Rev Med Pharmacol Sci 21 112-136
[10]
Wang Y(2014)Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury [J] Gastroenterology 147 109-9